Human Immune State-Guided Biomimetic Nanoadjuvant Reprograms Tumor-Draining Lymph Nodes to Enhance Cancer Immunotherapy

Abstract Effective antitumor immunity depends on immune priming within tumor-draining lymph nodes (TDLNs), yet therapeutic strategies targeting these immune-organizing sites remain limited. Here, we leveraged single-cell profiling of human colorectal cancer TDLNs to guide the design of a biomimetic nanoadjuvant for TDLN-targeted cancer immunotherapy. Single-cell and bulk transcriptomic analyses identified a LAMP3⁺ dendritic cell (DC) state associated with enhanced antigen presentation, costimulation, innate immune sensing, and antigen-experienced CD8⁺ T cell responses. Inspired by this human immune state, we engineered a DC membrane coated iridium-manganese oxide nanoadjuvant (IMOD NAs) loaded with ovalbumin (OVA) that integrates biomimetic recognition with coordinated redox and innate immune regulation. The DC membrane camouflage enhanced TDLN targeting, DC interaction and OVA delivery, whereas the IrMn oxide core simultaneously activated ROS-NF-κB and Mn²⁺-dependent STING signaling, thereby promoting DC maturation, migration, and antigen presentation. Remarkably, IMOD NAs reprogrammed TDLNs toward an immune-competent state, enhanced cytotoxic CD8⁺ T cell priming, and reduced regulatory T cell accumulation. In vivo, IMOD NAs suppressed tumor growth and markedly enhanced the therapeutic efficacy of PD-L1 blockade. Taken together, this study establishes a human immune state guided strategy for biomimetic nanoadjuvant design and demonstrates TDLN reprogramming as a complementary approach to improve cancer immunotherapy.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11589045/v1
Primary Topic
Immunotherapy and Immune Responses
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Human Immune State-Guided Biomimetic Nanoadjuvant Reprograms Tumor-Draining Lymph Nodes to Enhance Cancer Immunotherapy

Tiantongfei Jiang, Yaru Niu, Chan Li, Xu Guan et al.
5 links
Research Square
Immunotherapy and Immune Responses
preprint

Human Immune State-Guided Biomimetic Nanoadjuvant Reprograms Tumor-Draining Lymph Nodes to Enhance Cancer Immunotherapy

Tiantongfei Jiang, Yaru Niu, Chan Li, Xu Guan, Xishan Wang, Lei Zhao, Jian Ma, Xin Zhang, Yuxin Wan, Juan Xu
preprint en

Abstract

Abstract Effective antitumor immunity depends on immune priming within tumor-draining lymph nodes (TDLNs), yet therapeutic strategies targeting these immune-organizing sites remain limited. Here, we leveraged single-cell profiling of human colorectal cancer TDLNs to guide the design of a biomimetic nanoadjuvant for TDLN-targeted cancer immunotherapy. Single-cell and bulk transcriptomic analyses identified a LAMP3⁺ dendritic cell (DC) state associated with enhanced antigen presentation, costimulation, innate immune sensing, and antigen-experienced CD8⁺ T cell responses. Inspired by this human immune state, we engineered a DC membrane coated iridium-manganese oxide nanoadjuvant (IMOD NAs) loaded with ovalbumin (OVA) that integrates biomimetic recognition with coordinated redox and innate immune regulation. The DC membrane camouflage enhanced TDLN targeting, DC interaction and OVA delivery, whereas the IrMn oxide core simultaneously activated ROS-NF-κB and Mn²⁺-dependent STING signaling, thereby promoting DC maturation, migration, and antigen presentation. Remarkably, IMOD NAs reprogrammed TDLNs toward an immune-competent state, enhanced cytotoxic CD8⁺ T cell priming, and reduced regulatory T cell accumulation. In vivo, IMOD NAs suppressed tumor growth and markedly enhanced the therapeutic efficacy of PD-L1 blockade. Taken together, this study establishes a human immune state guided strategy for biomimetic nanoadjuvant design and demonstrates TDLN reprogramming as a complementary approach to improve cancer immunotherapy.

Research Square
Harbin Medical University (CN), China Medical University (TW), First Hospital of China Medical University (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN), Beijing Shijitan Hospital (CN), China Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon